Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Kidney Int. 2019 Aug 30;96(6):1346–1358. doi: 10.1016/j.kint.2019.07.026

Figure 4: Ferric citrate administration in mice with moderate CKD reduces FGF23 production.

Figure 4:

Levels of fecal phosphate (A), serum phosphate (B), bone Fgf23 expression (C), serum cFGF23 (D), serum iFGF23 (E), urine phosphate (F), serum 1,25(OH)2D (G), serum PTH (H), serum BUN (I) and urine albumin (J). Echocardiography analysis of left ventricular ejection fraction (K), stroke volume (L), cardiac output (M) and representative M-mode echocardiography (N). Measurements performed in 10 week old WT and Col4a3KO mice fed a mineral sufficient diet (Ctr) supplemented or not with 5% ferric citrate (FC) during 4 weeks. Data are presented as mean ± SE, n≥8 per group, p<0.05 vs.* WT-Ctr, $ WT-FC, & Col4a3KO-Ctr mice.